Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924401 | 0.82 | EPHX2 (0.41) | CHRM1POLBNPC1RAB9A | |
| SCHEMBL5743847 | 0.82 | ACE (0.55) | TSHR | |
| SCHEMBL4395886 | 0.81 | HPGD (0.47) | CHRM1HPGDTSHRGAA | |
| SCHEMBL5656404 | 0.81 | NPC1 (0.43) | L3MBTL1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4380565 | 0.80 | CHRM1 (0.51) | CHRM1 | |
| Hydrochloric Acid SCHEMBL4383425 | 0.79 | CHRM1 (0.50) | CHRM1 | |
| SCHEMBL1462830 | 0.78 | CYP1A2 (0.44) | CHRM1 | |
| SCHEMBL2466830 | 0.76 | EPHX1 (0.55) | L3MBTL1CHRM1POLB | |
| SCHEMBL5806034 | 0.76 | EPHX1 (0.41) | CHRM1POLBNPC1RAB9A | |
| SCHEMBL1461890 | 0.76 | EPHX1 (0.41) | CHRM1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | L3MBTL1 4795/4885CHRM1 1353/4885POLB 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.